From @Breakingviews: GSK decided to hive off its unit that makes Advil to concentrate on its remaining pharma business, which mainly makes vaccines for shingles. But a discounted valuation raises the prospect of risky M&amp;A, @aimeedonnellan explains  https://t.co/NDCkNR5xq2